Welcome to our dedicated page for Polypid Ltd. news (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on Polypid Ltd. stock.
PolyPid Ltd. (Nasdaq: PYPD) is publicly described as a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, prolonged-release therapeutics. News about PolyPid often centers on the development and regulatory progress of its lead product candidate, D-PLEX100, and on milestones related to its proprietary PLEX (Polymer-Lipid Encapsulation matriX) drug delivery technology.
Investors and observers following PYPD news will find updates on clinical trial results, particularly from the Phase 3 SHIELD II trial of D-PLEX100 in abdominal colorectal surgeries. Company press releases report that this trial met its primary and key secondary endpoints and demonstrated reductions in surgical site infections and related outcomes when D-PLEX100 was added to standard of care.
Regulatory developments are another major theme in PolyPid’s news flow. The company has announced that D-PLEX100 received Breakthrough Therapy designation from the U.S. Food and Drug Administration and has reported positive pre-NDA meeting minutes supporting a New Drug Application submission. News items also describe the FDA’s agreement to a rolling NDA review, which PolyPid highlights as an important step in its regulatory strategy.
Corporate and operational updates appear regularly, including GMP inspection outcomes for the company’s manufacturing facility by the Israeli Ministry of Health, which PolyPid states support its readiness for potential commercial production. Additional news covers participation in medical and investor conferences, board and management changes such as the appointment of a new chairman of the board, and financial results reported via quarterly updates.
For readers tracking PYPD, this news stream provides insight into PolyPid’s clinical progress, regulatory interactions, manufacturing readiness and capital markets activity, all framed around its goal of improving surgical outcomes with prolonged-release therapeutics.
PolyPid Ltd. (Nasdaq: PYPD) announced its participation in two investor conferences in November 2020. The company will present at the H.C. Wainwright 6th Annual Israel Conference on November 12 at 1:30 PM ET and at the Stifel 2020 Virtual Healthcare Conference on November 17 at 8:00 AM ET. Additionally, PolyPid will engage in one-on-one meetings during the AGP Virtual Healthcare Symposium on November 19. The company specializes in prolonging drug release using its proprietary PLEX technology, focusing on unmet medical needs, particularly with its lead product candidate, D-PLEX100, in Phase 3 trials.
PolyPid Ltd. (Nasdaq: PYPD) will report its third quarter 2020 financial results on November 11, 2020, before U.S. markets open. The company, focused on Phase 3 clinical development of its PLEX technology for prolonged-release therapeutics, will host a conference call at 8:30 AM ET to discuss results and business operations. Its lead candidate, D-PLEX100, targets surgical site infections and is in Phase 3 trials for various surgeries. More details can be found on the company's website.
PolyPid Ltd. (Nasdaq: PYPD) has initiated the SHIELD I trial, its first Phase 3 clinical study for D-PLEX100, aimed at preventing post-abdominal surgery incisional infections. The trial, which has enrolled its first patient, will assess the efficacy and safety of D-PLEX100 compared to standard care. Funded by a commitment to address surgical site infections, D-PLEX100 has previously shown significant promise in Phase 2 trials. Approximately 616 to 900 patients will be enrolled across 50 centers in the U.S., Europe, and Israel.
PolyPid Ltd. (Nasdaq: PYPD) has announced the pricing of its initial public offering (IPO) of 3,750,000 ordinary shares at $16.00 each, aiming to raise gross proceeds of $60 million. The shares are expected to start trading on the Nasdaq Global Market on June 26, 2020, with the offering set to close on June 30, 2020, pending customary conditions. The underwriters have a 30-day option to purchase an additional 562,500 shares at the IPO price. This offering follows the effectiveness of the registration statement by the SEC on June 25, 2020.